1. Home
  2. LEXX
  3. LEXX News

Latest Lexaria Bioscience Corp. (LEXX) News on January 22, 2025

LEXX

MT Newswires

7 days ago

Lexaria Bioscience Receives Ethics Board Approval for Oral Liraglutide Pilot Study

LEXX

ACCESS Newswire

7 days ago

Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval

LEXX

MT Newswires

8 days ago

Lexaria Bioscience Says Oral DehydraTECH-Tirzepatide Causes Fewer Adverse Effects

LEXX

ACCESS Newswire

8 days ago

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
LEXX

Simply Wall St.

8 days ago

Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Lexaria's Registered GLP-1 Study #4 Begins Dosing
LEXX

ACCESSWIRE

a month ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Lexaria Forms New Scientific Advisory Board
LEXX

ACCESSWIRE

a month ago

Lexaria Forms New Scientific Advisory Board

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
LEXX

ACCESSWIRE

a month ago

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide
LEXX

TipRanks

a month ago

Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
LEXX

ACCESSWIRE

a month ago

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

LEXX: Phase I Start Imminent
LEXX

Zacks Small Cap Research

2 months ago

LEXX: Phase I Start Imminent

LEXX

Newsfile

2 months ago

BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals

Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
LEXX

Simply Wall St.

2 months ago

Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
LEXX

ACCESSWIRE

2 months ago

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
LEXX

ACCESSWIRE

2 months ago

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
LEXX

ACCESSWIRE

2 months ago

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
LEXX

ACCESSWIRE

2 months ago

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

LEXX

MT Newswires

2 months ago

Lexaria Bioscience Gets Ethics Board Approval to Begin Dosing in Phase 1b Diabetes, Weight Loss Study

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
LEXX

ACCESSWIRE

2 months ago

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
LEXX

ACCESSWIRE

2 months ago

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
LEXX

ACCESSWIRE

3 months ago

Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study

Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
LEXX

ACCESSWIRE

3 months ago

Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
LEXX

ACCESSWIRE

3 months ago

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Companies Like Lexaria Bioscience (NASDAQ:LEXX) Are In A Position To Invest In Growth
LEXX

Simply Wall St.

3 months ago

Companies Like Lexaria Bioscience (NASDAQ:LEXX) Are In A Position To Invest In Growth

LEXX

MT Newswires

3 months ago

Lexaria Bioscience Expects to Raise $5 Million in Registered Direct Offering

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
LEXX

ACCESSWIRE

3 months ago

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

LEXX

MT Newswires

3 months ago

Lexaria Bioscience Launches Human Study of DehydraTECH-Processed Tirzepatide

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
LEXX

ACCESSWIRE

3 months ago

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Lexaria Updates Current GLP-1 Market
LEXX

ACCESSWIRE

3 months ago

Lexaria Updates Current GLP-1 Market

LEXX

MT Newswires

4 months ago

Lexaria Bioscience Names Michael Shankman CFO

Lexaria Appoints Michael Shankman as Chief Financial Officer
LEXX

ACCESSWIRE

4 months ago

Lexaria Appoints Michael Shankman as Chief Financial Officer

LEXX

MT Newswires

4 months ago

Lexaria Bioscience Receives Approval From Independent Review Board for Pilot Study of Tirzepatide

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
LEXX

ACCESSWIRE

4 months ago

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3

LEXX

Zacks Small Cap Research

4 months ago

LEXX: Changing Gears: Christopher Takes Over as CEO

LEXX

MT Newswires

5 months ago

Lexaria Bioscience Taps InVivo Therapeutics CFO Richard Christopher As New CEO

Lexaria Releases Strategic Letter from the Outgoing CEO
LEXX

ACCESSWIRE

5 months ago

Lexaria Releases Strategic Letter from the Outgoing CEO

Lexaria Welcomes Industry Veteran as New CEO
LEXX

ACCESSWIRE

5 months ago

Lexaria Welcomes Industry Veteran as New CEO

LEXX

ACCESSWIRE

5 months ago

Lexaria Enters a Material Transfer Agreement for DehydraTECH Research

LEXX

MT Newswires

5 months ago

Lexaria Bioscience Says Its Second Weight Loss Drug Human Study Showed No Adverse Events

LEXX

ACCESSWIRE

5 months ago

Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules

First Results from Lexaria's Second GLP-1 Human Pilot Study
LEXX

ACCESSWIRE

5 months ago

First Results from Lexaria's Second GLP-1 Human Pilot Study

LEXX

MT Newswires

5 months ago

Lexaria Bioscience Says Liraglutide 'Outperforming' Semaglutide in Animal Weight Loss Study

Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
LEXX

ACCESSWIRE

5 months ago

Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

LEXX

MT Newswires

5 months ago

Lexaria Bioscience Reports Blood Sugar Reductions in Ongoing Diabetes Study; Shares Fall

Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
LEXX

ACCESSWIRE

5 months ago

Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Results from Lexaria's Molecular Characterization Study
LEXX

ACCESSWIRE

5 months ago

Positive Results from Lexaria's Molecular Characterization Study

LEXX: GLP-1 Agonist Program Updates
LEXX

Zacks Small Cap Research

6 months ago

LEXX: GLP-1 Agonist Program Updates

Lexaria Bioscience Third Quarter 2024 Earnings: Misses Expectations
LEXX

Simply Wall St.

6 months ago

Lexaria Bioscience Third Quarter 2024 Earnings: Misses Expectations

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
LEXX

ACCESSWIRE

6 months ago

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

Lexaria Preparing For Strategic Growth
LEXX

ACCESSWIRE

6 months ago

Lexaria Preparing For Strategic Growth

Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
LEXX

ACCESSWIRE

6 months ago

Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study

LEXX

MT Newswires

6 months ago

Lexaria Bioscience Secures New Antiviral Drug Delivery, Epilepsy Patents

Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
LEXX

ACCESSWIRE

6 months ago

Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy

LEXX

MT Newswires

7 months ago

Lexaria Bioscience Hires Contract Research Organization For 12-week Study

Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
LEXX

ACCESSWIRE

7 months ago

Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study

LEXX

MT Newswires

8 months ago

Lexaria Bioscience Completes Dosing in Second Round of Semaglutide Formulations Human Pilot Study

Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
LEXX

ACCESSWIRE

8 months ago

Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study

Lexaria Awards Contract For Third GLP-1 Human Pilot Study
LEXX

ACCESSWIRE

8 months ago

Lexaria Awards Contract For Third GLP-1 Human Pilot Study

LEXX

MT Newswires

8 months ago

Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise

Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
LEXX

ACCESSWIRE

8 months ago

Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy

Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study
LEXX

ACCESSWIRE

8 months ago

Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study

Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation
LEXX

Simply Wall St.

8 months ago

Here's Why We're Watching Lexaria Bioscience's (NASDAQ:LEXX) Cash Burn Situation

Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
LEXX

ACCESSWIRE

8 months ago

Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study

Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
LEXX

ACCESSWIRE

9 months ago

Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
LEXX

ACCESSWIRE

9 months ago

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance

LEXX: Begin with the End in Mind
LEXX

Zacks Small Cap Research

9 months ago

LEXX: Begin with the End in Mind

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
LEXX

ACCESSWIRE

9 months ago

Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study

Lexaria Awarded New Patents
LEXX

ACCESSWIRE

10 months ago

Lexaria Awarded New Patents

LEXX

Newsfile

10 months ago

Lexaria to Present at The LD Micro Invitational XIV

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
LEXX

ACCESSWIRE

10 months ago

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Lexaria Awards Contract For Next GLP-1 Human Pilot Study
LEXX

ACCESSWIRE

a year ago

Lexaria Awards Contract For Next GLP-1 Human Pilot Study

Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
LEXX

ACCESSWIRE

a year ago

Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1

7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
LEXX

ACCESSWIRE

a year ago

7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study

Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
LEXX

ACCESSWIRE

a year ago

Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year
LEXX

Simply Wall St.

a year ago

This Lexaria Bioscience Insider Increased Their Holding By 23% Last Year

Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
LEXX

ACCESSWIRE

a year ago

Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
LEXX

ACCESSWIRE

a year ago

Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria's Submits Investigational New Drug Application
LEXX

ACCESSWIRE

a year ago

Lexaria's Submits Investigational New Drug Application

Lexaria Releases Annual Letter from the CEO
LEXX

ACCESSWIRE

a year ago

Lexaria Releases Annual Letter from the CEO

LEXX’ Sweet Opportunity in GLP-1s
LEXX

Zacks Small Cap Research

a year ago

LEXX’ Sweet Opportunity in GLP-1s

Kentucky First Federal Bancorp Announces Suspension of Quarterly Cash Dividend
LEXX

GlobeNewswire

a year ago

Kentucky First Federal Bancorp Announces Suspension of Quarterly Cash Dividend

Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
LEXX

ACCESSWIRE

a year ago

Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program

Why Fast-paced Mover Fathom Holdings (FTHM) Is a Great Choice for Value Investors
LEXX

Zacks

a year ago

Why Fast-paced Mover Fathom Holdings (FTHM) Is a Great Choice for Value Investors

Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
LEXX

GlobeNewswire

a year ago

Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
LEXX

GlobeNewswire

a year ago

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform

LEXX

GlobeNewswire

a year ago

Aeries Technology to Participate at the 26th Annual ICR Conference

Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide
LEXX

ACCESSWIRE

a year ago

Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide

Argo Blockchain PLC Announces Total Voting Rights & Share Capital
LEXX

ACCESSWIRE

a year ago

Argo Blockchain PLC Announces Total Voting Rights & Share Capital

How Did Aeries Technology, Inc's (NASDAQ:AERT) 13% ROE Fare Against The Industry?
LEXX

Simply Wall St.

a year ago

How Did Aeries Technology, Inc's (NASDAQ:AERT) 13% ROE Fare Against The Industry?

Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement
LEXX

CNW Group

a year ago

Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration Statement

Lexaria's Investigational New Drug Application Filing Update
LEXX

ACCESSWIRE

a year ago

Lexaria's Investigational New Drug Application Filing Update

LEXX

PR Newswire

a year ago

iClick Interactive Asia Group Limited Enters into a Definitive Merger Agreement for Going-Private Transaction

LEXX

GuruFocus.com

a year ago

Abacus Life Inc (ABL) Reports 20% Revenue Growth in Q3 2023

Abacus Life Reports Third Quarter 2023 Results
LEXX

GlobeNewswire

a year ago

Abacus Life Reports Third Quarter 2023 Results

LEXX

GuruFocus.com

a year ago

Candel Therapeutics Inc (CADL) Reports Q3 2023 Financial Results and Clinical Progress

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
LEXX

GlobeNewswire

a year ago

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
LEXX

GlobeNewswire

a year ago

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
LEXX

GlobeNewswire

a year ago

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Share on Social Networks: